1-20-11 Daily Small Cap Market News and Stock Highlights from SmallCapVoice.com

Angela Moon – Reuters

Wall St falls for second day as materials, tech weigh

NEW YORK (Reuters) – Stocks fell on Thursday as upbeat economic data on jobs and housing failed to offset a selloff in the technology and materials sectors.

Technology stocks were weighed by networking/cloud computing companies after F5 Networks Inc gave a gloomy outlook, while energy and material stocks were pressured by a sharp decline in crude oil prices.

The Dow Jones industrial average dropped 74.13 points, or 0.63 percent, at 11,751.16. The Standard & Poor's 500 Index was down 9.72 points, or 0.76 percent, at 1,272.20. The Nasdaq Composite Index slid 32.31 points, or 1.19 percent, at 2,693.05.

The decline came a day after Wall Street suffered its worst drop in nearly two months on disappointing results from banks. Investors were concerned the slump may grow worse.

Yesterday's Top Performing Small Cap Stock:

VitaminSpice VTMS

VitaminSpice was a SmallCapVoice.com top performer closing up over 24% on trading volume of 803,426 shares.

VitaminSpiceTM is the pioneer of a new category of vitamin-enhanced seasonings and condiments within the $33 billion US functional food and beverage market. The inspired creation of a father and molecular biologist, VitaminSpice makes it easy for busy families to naturally boost the nutritional value of their meals with spices, seasonings and condiments that enliven the palate. VitaminSpice's first product line of proprietary spice and vitamin blends offers a convenient and effective way to nourish the body, and is perfect for anyone who wants to enhance nutritional intake without the discomfort of swallowing vitamin pills. VitaminSpice is currently available online and in select retail outlets.

Detailed Quote >>

Today's SmallCapVoice.com Hot Stock to Watch:

Tootie Pie Company TOOT

SA-weet! Sunday is National Pie Day

Oh yes, there truly is a day called National Pie Day.

Each year, the American Pie Council (APC), its associate members and pie lovers from around the country celebrate National Pie Day on 1/23 as a tribute to the wholesome fun and goodness of pie.

What's more, it turns out that pies are the top restaurant trend for 2011 according to the Nation's Restaurant News.

Other Small Cap News

Chelsea Therapeutics CHTP

Chelsea Therapeutics Reports Data Demonstrating Sustained Symptomatic Benefit of Northera in Neurogenic Orthostatic Hypotension Over 12-Month Treatment Period

CHARLOTTE, NC, Jan. 20, 2011 (GLOBE NEWSWIRE) — Chelsea Therapeutics International, Ltd. CHTP reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA(TM) (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period. The data also validate that the drug is safe and well tolerated following extended dosing up to two years.

Soligenix, Inc. SNGX

Soligenix Receives FDA Orphan Drug Designation for RiVax for the Prevention of Ricin Intoxication

PRINCETON, N.J., Jan. 20, 2011 /PRNewswire/ — Soligenix, Inc. (OTC Bulletin Board:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to RiVax™ for the prevention of ricin intoxication. RiVax™ is a proprietary vaccine that contains a recombinant subunit of the A chain of ricin toxin which induces ricin neutralizing antibodies in humans and animals.

Cytori Therapeutics, Inc. CYTX

Cytori Approved to Initiate Pivotal Stem & Regenerative Cell Heart Attack Trial in Europe; First ADVANCE Trial Site to Begin Enrollment in the Netherlands

SAN DIEGO, CA–(Marketwire – 01/20/11) – Cytori CYTX received approval from The Netherlands to initiate a pivotal European trial, named ADVANCE, to investigate adipose-derived stem and regenerative cells (ADRCs), processed by the Celution® One System, in the treatment of patients with acute heart attacks. This is the first country and trial-center approval for ADVANCE. Additional country and trial-center approvals are anticipated throughout Europe during the first half of 2011. One of the goals of the trial is to expand the Celution® System CE Mark to include acute heart attack claims and to provide economic data to justify its implementation and reimbursement.

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN)

Teva Pharmaceutical Increases Its Investment in Rexahn for the Continued Research and Development of the Pre-Clinical Anti-Cancer Compound, RX-3117

ROCKVILLE, Md.–(BUSINESS WIRE)– Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, announced that Teva Pharmaceutical Industries Limited (Teva) purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share. This investment by Teva was made pursuant to the terms of the Securities Purchase Agreement, dated June 26, 2009, as amended. The investment money will be used for the purpose of supporting the research and development program for the pre-clinical stage, anti-cancer compound RX-3117. After this transaction, Teva will own 6.29% of the outstanding shares of Rexahn.

Wuhan General Group WUHN

Wuhan General's Subsidiary Wins Bid for Wuhan Subway Systems

WUHAN, China, Jan. 20, 2011 /PRNewswire-Asia-FirstCall/ — Wuhan General Group (China), Inc. WUHN (“Wuhan General” or the “Company”), a leading manufacturer of industrial blowers and turbines in China, operating through its subsidiaries, Wuhan Blower Co., Ltd. (“Wuhan Blower”), Wuhan Generating Equipment Co., Ltd. (“Wuhan Generating”) and Wuhan Sungreen Environment Protection Equipment Co., Ltd. (“Wuhan Sungreen”), today announced that on January 4, 2011, Wuhan Blower won a bid from the Wuhan Metro Group Co., Ltd. (“Wuhan Metro”) to supply blowers for the subway systems for a contract price of RMB 4.40 million ($0.67 million). The Company believes this initial order opens the door for additional opportunities from Wuhan Metro and is actively bidding for orders.

Orbit International Corp. ORBT

Orbit International Corp. Receives Follow-on Order of Approximately $400,000 for Common Transponder Program

Orbit Instrument Division Bookings for 2010 Exceed $11 Million

HAUPPAUGE, N.Y.–(BUSINESS WIRE)– Orbit International Corp. ORBT, an electronics manufacturer and software solution provider, today announced that its Electronics Group received a follow-on order valued at approximately $400,000 for Remote Control Units (“RCUs”) to support the ongoing Common Transponder Program requirements of the U.S. Navy and U.S. Army. This order was received by the Company's Orbit Instrument Division. Deliveries under this follow-on contract are expected during the fourth quarter of 2011.

Radient Pharmaceuticals Corporation (NYSE Amex: RPC)

Radient Pharmaceuticals Receives Updated European Union Certification for Onko-Sure(R); CE Mark Opens Large Market for Company's IVD Cancer Test

TUSTIN, CA–(Marketwire – 01/20/11) – Radient Pharmaceuticals Corporation (RPC) RPC, a US-based company specializing in the research, development, and international commercialization of In Vitro Diagnostic cancer tests, announced today it has received CE-Mark approval from the European Union (EU) for the use of its Onko-Sure® In Vitro diagnostic (IVD) cancer test as a pan tumor marker for cancer. RPC's new CE-Mark Certificate for Onko-Sure® is dated December 28, 2010 and provides product access to 27 countries with a combined population of approximately 500 million.

About SmallCapVoice.com

SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide. Known for its ability to help emerging growth companies build a following among retail and institutional investors, SmallCapVoice.com utilizes its stock newsletter to feature its audio interviews, as well small cap company's financial news releases. SmallCapVoice.com also offers individual investors with all the tools they need to make informed decisions about the stocks they are interested in. Tools like our stock charts, stock alerts, and our company information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.

The SmallCapVoice.com, Inc. Daily Highlights is an electronic publication, and is for informational purposes only. The Small Cap Voice Daily Highlights covers both client and non client issuers. Non client issuer's news is listed under other small cap news. SmallCapVoice is an electronic publication providing information on selected public companies. All companies profiled on this website pay cash or restricted stock to SmallCapVoice as consideration for the electronic dissemination of the company's information and our comments about the company. Section 17(b) of the Securities Act of 1933 requires that SmallCapVoice fully disclose the type consideration (i.e. cash, restricted stock, and restricted stock with registration rights, stock options, stock warrants, or other type consideration) and the specific amount of the consideration our company receives or will receive, directly or indirectly, from an issuer, underwriter, or dealer. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell the securities of the profiled companies. SmallCapVoice is not a registered investment advisor or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. The information contained in our website, e-mail communications and publications are carefully compiled by SmallCapVoice from public sources that we believe to be reliable. SmallCapVoice, however, does not guarantee the accuracy of any information contained in our website, e-mail communications or publications. This material is not a substitute for either one's own thorough investigation of an investment opportunity or the exercise of good business judgment. SmallCapVoice does not endorse, independently verify, or assert the truthfulness or reliability of any statements or data obtained from third party sources that are published by us about the profiled companies in our website articles, e-mail communications or publications, but we do not publish information that we know is incorrect. Investors should not rely solely on the information contained in our website, e-mail communications or publications when making investment decisions. Instead, investors should use the information provided on the profiled companies as a starting point for conducting additional research that will permit them to form their own opinions regarding the appropriateness of an investment in the profiled company's securities. SmallCapVoice does not warrant, represent or guaranty that there has been no change in the affairs of the profiled company since the date that information was published on this website, in e-mail communications or in our publications regarding a profiled company or after the date of the profiled company's press releases or other information disseminated via our website or publications. If you become aware of any change of circumstances related to any website article, e-mail communication or publication, please notify us immediately. See the Contact Us page for the appropriate e-mail address. The information contained in our website, e-mail communications and publications pertains to microcap, small cap and/or other thinly traded securities which by their very nature involve an extremely high degree of risk. An investment in these type of securities could result in the loss of some or all of an investment in the company. In addition, due to the illiquid nature of some of these securities, an investor may find encounter difficulties in liquidating the securities. SmallCapVoice may liquidate the stock consideration it receives at any time it deems it appropriate to do so after the required six-month holding period has run after the completion of the services for which SmallCapVoice was paid in stock. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company's securities. The following companies have paid, and/or have agreed to pay SmallCapVoice to: distribute the company's information and reports on this website, to send e-mail communications; to send publications by mail, to post company Internet links on our website, and to compile and/or to distribute reports in an e-mail newsletter.

We encourage our readers to use caution when investing and educate themselves at the web sites of the Securities and Exchange Commission (“SEC”) at www.sec.gov and/or the National Association of Securities Dealers (“NASD”) at www.nasd.com. We encourage you to study the SEC's policies regarding online newsletters at http://www.sec.gov/answers/newsltr.htm. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our site.

Contact:

Stuart T. Smith CEO
512-267-2430
ssmith@smallcapvoice.com
http://www.smallcapvoice.com